coiled spring?, page-13

The difference here is that Prana do not have a failed trial.
Obviously if Prana picked up the transcription mistakes by the trial docs, They have seen the blinded data and are expecting a "robust" result to take to the FDA. That is plain language, and it does not sound like a failure.
Regarding PRR, that was a risky trial for a therapeutic cancer vaccine. What eventually sold Provenge to the FDA was as I recall a few months survival advantage in PC over taxotere. I know a few months was not a lot, but when you consider the plant alkaloid taxotere has some pretty horrendous side effects, then something just a little bit better with no side effects, would have to be a winner.Then there was a cutoff point regarding gleason scores(disease stage).
PRRs little phase2 was probably always a longshot, and not powered to demonstrate survival. When I was following DNDN, the FDA standard was overall survival, and that was always going to take a long phase 3 to prove. PFS would have been good, but I don't think it can be written off just yet.

Anyway at this point PBT2 Reach2HD has not missed any trial endpoints and the data is still being crunched.